Investing.com - Biomerieux reported on Wednesday second quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Biomerieux announced earnings per share of €1.93 on revenue of €820.9M. Analysts polled by Investing.com anticipated EPS of €2.22 on revenue of €719.4M.
Biomerieux shares are down 26% from the beginning of the year, still down 31.49% from its 52 week high of €133.20 set on November 26, 2021. They are under-performing the STOXX 600 which is down 14.9% from the start of the year.
Biomerieux follows other major Healthcare sector earnings this month
Biomerieux's report follows an earnings missed by Valneva on August 11, who reported EPS of €-1.34 on revenue of €71.4M, compared to forecasts EPS of €-0.42 on revenue of €18.2M.
Cellectis had beat expectations on August 4 with second quarter EPS of €-0.4132 on revenue of €2.72M, compared to forecast for EPS of €-0.4938 on revenue of €22.43M.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar